Published in Schizophr Bull on June 23, 2014
Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci (2015) 0.95
The "Reading the Mind in the Eyes" Test: Complete Absence of Typical Sex Difference in ~400 Men and Women with Autism. PLoS One (2015) 0.87
A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia. J Clin Psychopharmacol (2017) 0.82
The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders. Mol Psychiatry (2015) 0.79
Unsupervised data-driven stratification of mentalizing heterogeneity in autism. Sci Rep (2016) 0.78
Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia. Schizophr Res (2016) 0.76
Failure of the Nemo Trial: Bumetanide Is a Promising Agent to Treat Many Brain Disorders but Not Newborn Seizures. Front Cell Neurosci (2016) 0.75
Reversal of social deficits by subchronic oxytocin in two autism mouse models. Neuropharmacology (2015) 0.75
A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia. Schizophr Res (2017) 0.75
Insulin-regulated aminopeptidase immunoreactivity is abundantly present in human hypothalamus and posterior pituitary gland, with reduced expression in paraventricular and suprachiasmatic neurons in chronic schizophrenia. Eur Arch Psychiatry Clin Neurosci (2016) 0.75
A Review of the Safety, Efficacy and Mechanisms of Delivery of Nasal Oxytocin in Children: Therapeutic Potential for Autism and Prader-Willi Syndrome, and Recommendations for Future Research. Paediatr Drugs (2017) 0.75
G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods (2007) 50.83
Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med (2002) 24.22
The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther (1995) 11.36
The "Reading the Mind in the Eyes" Test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry (2001) 9.51
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol (1998) 9.33
The empathy quotient: an investigation of adults with Asperger syndrome or high functioning autism, and normal sex differences. J Autism Dev Disord (2004) 6.21
The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull (2006) 5.59
Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. Psychol Methods (2002) 5.23
Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci (2011) 5.03
Rethinking schizophrenia. Nature (2010) 4.85
The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatry (1990) 3.75
Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. Psychoneuroendocrinology (2012) 3.30
Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry (2009) 3.24
Targeted primary care-based mental health services for young Australians. Med J Aust (2012) 3.07
Frontal lobe contributions to theory of mind. J Cogn Neurosci (1998) 2.70
Social skills performance assessment among older patients with schizophrenia. Schizophr Res (2001) 2.53
Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry (1999) 2.06
Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br J Addict (1992) 1.96
The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry (2001) 1.94
Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry (2010) 1.81
Social cognition in schizophrenia, Part 1: performance across phase of illness. Schizophr Bull (2011) 1.77
A critical review of the influence of oxytocin nasal spray on social cognition in humans: evidence and future directions. Horm Behav (2012) 1.67
Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr Res (2010) 1.52
Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr Res (2011) 1.49
Social cognition and interaction training (SCIT) for outpatients with schizophrenia: a preliminary study. Psychiatry Res (2009) 1.47
Best practices: The development of the Social Cognition and Interaction Training program for schizophrenia spectrum disorders. Psychiatr Serv (2007) 1.35
Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr Res (2007) 1.32
The Ambiguous Intentions Hostility Questionnaire (AIHQ): a new measure for evaluating hostile social-cognitive biases in paranoia. Cogn Neuropsychiatry (2007) 1.30
Five domains of interpersonal competence in peer relationships. J Pers Soc Psychol (1988) 1.29
Amygdala damage impairs emotion recognition from scenes only when they contain facial expressions. Neuropsychologia (2003) 1.28
What we know: findings that every theory of schizophrenia should explain. Schizophr Bull (2009) 1.27
Sharing secrets: oxytocin and trust in schizophrenia. Soc Neurosci (2008) 1.24
Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs (2013) 1.24
Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia. Psychopharmacology (Berl) (2011) 1.19
Neurobiological markers of illness onset in psychosis and schizophrenia: The search for a moving target. Neuropsychol Rev (2009) 1.16
Emotion recognition and oxytocin in patients with schizophrenia. Psychol Med (2011) 1.15
Effects of single dose intranasal oxytocin on social cognition in schizophrenia. Schizophr Res (2013) 1.09
Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia. Schizophr Bull (2010) 1.02
Oxytocin as a natural antipsychotic: a study using oxytocin knockout mice. Mol Psychiatry (2008) 1.01
Low doses of oxytocin facilitate social recognition in rats. Psychopharmacology (Berl) (1992) 0.98
A pilot study to investigate the effectiveness of emotion recognition remediation in schizophrenia using the micro-expression training tool. Br J Clin Psychol (2006) 0.97
A randomized, controlled trial of Social Cognition and Interaction Training (SCIT) for outpatients with schizophrenia spectrum disorders. Br J Clin Psychol (2014) 0.96
Clinical classification in mental health at the cross-roads: which direction next? BMC Med (2013) 0.87
Defective Self and/or Other Mentalising in Schizophrenia: A Cognitive Neuropsychological Approach. Cogn Neuropsychiatry (1997) 0.86
Transportability and feasibility of Social Cognition And Interaction Training (SCIT) in community settings. Behav Cogn Psychother (2009) 0.85
An open clinical trial assessing a novel training program for social cognitive impairment in schizophrenia. Australas Psychiatry (2013) 0.80
Social cognition training as an intervention for improving functional outcome in first-episode psychosis: a feasibility study. Early Interv Psychiatry (2013) 0.80
Social cognitive performance as a marker of positive psychotic symptoms in young people seeking help for mental health problems. Schizophr Res (2013) 0.79